Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Metastasis | Research

Significance of circulating tumor cells detection in tumor diagnosis and monitoring

Authors: Yuanrui Liu, Rong Zhao, Zaichun Xie, Zhiyu Pang, Shengjie Chen, Qian Xu, Zhanfeng Zhang

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

To detect circulating tumor cells (CTCs) in the peripheral blood of patients with tumor, and to analyze the significance of CTC detection in tumor diagnosis and monitoring. In the present study, peripheral blood was collected from 125 patients with tumor, and CTCs were isolated and identified. Differences in CTC number and subtype detection were analyzed for different tumor diseases and stages. CTCs were detected in 122 of the 125 patients with tumor, with a positive rate of 97.6%. The number of CTCs increases in patients with vascular metastasis. The number of mesenchymal CTCs increases in patients with lymph node or vascular metastasis. The average ratio of epithelial CTCs in each positive sample decreases in the later stages of cancer compared with the earlier stages, while the average ratio of mesenchymal CTCs increases in the later stages of cancer compared with the earlier stages. The results showed that CTCs with mesenchymal phenotypes are closely related to lymph node or vascular metastasis. CTC detection can help with early diagnosis of tumor diseases. Continuous monitoring of changes in CTCs number and subtypes can assist clinical judgment of tumor disease development status and prognosis.
Literature
1.
go back to reference Goenka A, Tiek D, Song X, Huang T, Hu B, Cheng SY. The many facets of Therapy Resistance and Tumor Recurrence in Glioblastoma. CELLS-BASEL 2021, 10(3). Goenka A, Tiek D, Song X, Huang T, Hu B, Cheng SY. The many facets of Therapy Resistance and Tumor Recurrence in Glioblastoma. CELLS-BASEL 2021, 10(3).
2.
go back to reference Groenendijk A, Spreafico F, de Krijger RR, Drost J, Brok J, Perotti D, van Tinteren H, Venkatramani R, Godzinski J, Rube C et al. Prognostic Factors for Wilms Tumor Recurrence: A Review of the Literature. CANCERS 2021, 13(13). Groenendijk A, Spreafico F, de Krijger RR, Drost J, Brok J, Perotti D, van Tinteren H, Venkatramani R, Godzinski J, Rube C et al. Prognostic Factors for Wilms Tumor Recurrence: A Review of the Literature. CANCERS 2021, 13(13).
3.
go back to reference Li Y, Ma Y, Wu Z, Xie R, Zeng F, Cai H, Lui S, Song B, Chen L, Wu M. Advanced Imaging techniques for differentiating pseudoprogression and Tumor Recurrence after Immunotherapy for Glioblastoma. FRONT IMMUNOL. 2021;12:790674.CrossRefPubMedPubMedCentral Li Y, Ma Y, Wu Z, Xie R, Zeng F, Cai H, Lui S, Song B, Chen L, Wu M. Advanced Imaging techniques for differentiating pseudoprogression and Tumor Recurrence after Immunotherapy for Glioblastoma. FRONT IMMUNOL. 2021;12:790674.CrossRefPubMedPubMedCentral
4.
go back to reference Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL, Martin RM, Young GJ, Walsh EI, Bryant RJ, et al. Fifteen-year outcomes after monitoring, Surgery, or Radiotherapy for Prostate Cancer. NEW ENGL J MED. 2023;388(17):1547–58.CrossRefPubMed Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL, Martin RM, Young GJ, Walsh EI, Bryant RJ, et al. Fifteen-year outcomes after monitoring, Surgery, or Radiotherapy for Prostate Cancer. NEW ENGL J MED. 2023;388(17):1547–58.CrossRefPubMed
5.
go back to reference Lin D, Shen L, Luo M, Zhang K, Li J, Yang Q, Zhu F, Zhou D, Zheng S, Chen Y, et al. Circulating Tumor cells: biology and clinical significance. SIGNAL TRANSDUCT TAR. 2021;6(1):404.CrossRef Lin D, Shen L, Luo M, Zhang K, Li J, Yang Q, Zhu F, Zhou D, Zheng S, Chen Y, et al. Circulating Tumor cells: biology and clinical significance. SIGNAL TRANSDUCT TAR. 2021;6(1):404.CrossRef
6.
go back to reference Chang MC, Chang YT, Chen JY, Jeng YM, Yang CY, Tien YW, Yang SH, Chen HL, Liang TY, Wang CF, et al. Clinical significance of circulating Tumor Microemboli as a prognostic marker in patients with pancreatic ductal adenocarcinoma. CLIN CHEM. 2016;62(3):505–13.CrossRefPubMed Chang MC, Chang YT, Chen JY, Jeng YM, Yang CY, Tien YW, Yang SH, Chen HL, Liang TY, Wang CF, et al. Clinical significance of circulating Tumor Microemboli as a prognostic marker in patients with pancreatic ductal adenocarcinoma. CLIN CHEM. 2016;62(3):505–13.CrossRefPubMed
7.
go back to reference Tao J, Zhu L, Yakoub M, Reissfelder C, Loges S, Scholch S. Cell-cell interactions drive Metastasis of circulating Tumor Microemboli. CANCER RES. 2022;82(15):2661–71.CrossRefPubMed Tao J, Zhu L, Yakoub M, Reissfelder C, Loges S, Scholch S. Cell-cell interactions drive Metastasis of circulating Tumor Microemboli. CANCER RES. 2022;82(15):2661–71.CrossRefPubMed
8.
go back to reference Jiang L, Yang H, Cheng W, Ni Z, Xiang N. Droplet microfluidics for CTC-based liquid biopsy: a review. ANALYST. 2023;148(2):203–21.CrossRefPubMed Jiang L, Yang H, Cheng W, Ni Z, Xiang N. Droplet microfluidics for CTC-based liquid biopsy: a review. ANALYST. 2023;148(2):203–21.CrossRefPubMed
9.
go back to reference Chauhan A, Kaur R, Ghoshal S, Pal A. Exploration of circulating Tumour Cell (CTC) Biology: a paradigm shift in Liquid Biopsy. INDIAN J CLIN BIOCHE. 2021;36(2):131–42.CrossRef Chauhan A, Kaur R, Ghoshal S, Pal A. Exploration of circulating Tumour Cell (CTC) Biology: a paradigm shift in Liquid Biopsy. INDIAN J CLIN BIOCHE. 2021;36(2):131–42.CrossRef
10.
go back to reference Zhang X, Guo X, Zong Y, Xu C, Wang J, Zhang B, Liu C, Gong Y, Xue L, Ma L, et al. CTCs detection from intraoperative salvaged blood in RCC-IVC thrombus patients by negative enrichment and iFISH identification: a preliminary study. BMC UROL. 2021;21(1):89.CrossRefPubMedPubMedCentral Zhang X, Guo X, Zong Y, Xu C, Wang J, Zhang B, Liu C, Gong Y, Xue L, Ma L, et al. CTCs detection from intraoperative salvaged blood in RCC-IVC thrombus patients by negative enrichment and iFISH identification: a preliminary study. BMC UROL. 2021;21(1):89.CrossRefPubMedPubMedCentral
11.
go back to reference Costa C, Davila-Ibanez AB. Methodology for the isolation and analysis of CTCs. ADV EXP MED BIOL. 2020;1220:45–59.CrossRefPubMed Costa C, Davila-Ibanez AB. Methodology for the isolation and analysis of CTCs. ADV EXP MED BIOL. 2020;1220:45–59.CrossRefPubMed
12.
go back to reference Tsongalis GJ. Branched DNA technology in molecular diagnostics. AM J CLIN PATHOL. 2006;126(3):448–53.CrossRefPubMed Tsongalis GJ. Branched DNA technology in molecular diagnostics. AM J CLIN PATHOL. 2006;126(3):448–53.CrossRefPubMed
13.
go back to reference Wu S, Liu S, Liu Z, Huang J, Pu X, Li J, Yang D, Deng H, Yang N, Xu J. Classification of circulating Tumor cells by epithelial-mesenchymal transition markers. PLoS ONE. 2015;10(4):e123976.CrossRef Wu S, Liu S, Liu Z, Huang J, Pu X, Li J, Yang D, Deng H, Yang N, Xu J. Classification of circulating Tumor cells by epithelial-mesenchymal transition markers. PLoS ONE. 2015;10(4):e123976.CrossRef
14.
go back to reference Ahn KS, O’Brien DR, Kim YH, Kim TS, Yamada H, Park JW, Park SJ, Kim SH, Zhang C, Li H, et al. Associations of serum Tumor biomarkers with Integrated genomic and clinical characteristics of Hepatocellular Carcinoma. LIVER CANCER. 2021;10(6):593–605.CrossRefPubMedPubMedCentral Ahn KS, O’Brien DR, Kim YH, Kim TS, Yamada H, Park JW, Park SJ, Kim SH, Zhang C, Li H, et al. Associations of serum Tumor biomarkers with Integrated genomic and clinical characteristics of Hepatocellular Carcinoma. LIVER CANCER. 2021;10(6):593–605.CrossRefPubMedPubMedCentral
15.
go back to reference Bratu O, Mischianu D, Marcu D, Spinu D, Iorga L, Cherciu A, Balescu I, Bacalbasa N, Diaconu C, Savu C, et al. Renal Tumor biomarkers (review). EXP THER MED. 2021;22(5):1297.CrossRefPubMedPubMedCentral Bratu O, Mischianu D, Marcu D, Spinu D, Iorga L, Cherciu A, Balescu I, Bacalbasa N, Diaconu C, Savu C, et al. Renal Tumor biomarkers (review). EXP THER MED. 2021;22(5):1297.CrossRefPubMedPubMedCentral
16.
go back to reference Komarnicki P, Musialkiewicz J, Stanska A, Maciejewski A, Gut P, Mastorakos G, Ruchala M. Circulating Neuroendocrine Tumor Biomarkers: Past, Present and Future. J CLIN MED 2022, 11(19). Komarnicki P, Musialkiewicz J, Stanska A, Maciejewski A, Gut P, Mastorakos G, Ruchala M. Circulating Neuroendocrine Tumor Biomarkers: Past, Present and Future. J CLIN MED 2022, 11(19).
17.
go back to reference Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as Tumor marker in Lung cancer. Lung Cancer. 2012;76(2):138–43.CrossRefPubMed Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as Tumor marker in Lung cancer. Lung Cancer. 2012;76(2):138–43.CrossRefPubMed
18.
go back to reference Luo G, Jin K, Deng S, Cheng H, Fan Z, Gong Y, Qian Y, Huang Q, Ni Q, Liu C, et al. Roles of CA19-9 in Pancreatic cancer: Biomarker, predictor and promoter. BBA-REV CANCER. 2021;1875(2):188409. Luo G, Jin K, Deng S, Cheng H, Fan Z, Gong Y, Qian Y, Huang Q, Ni Q, Liu C, et al. Roles of CA19-9 in Pancreatic cancer: Biomarker, predictor and promoter. BBA-REV CANCER. 2021;1875(2):188409.
19.
go back to reference Lakes J, Arsov C. [PSA screening and molecular markers]. UROLOGE. 2019;58(5):486–93.CrossRef Lakes J, Arsov C. [PSA screening and molecular markers]. UROLOGE. 2019;58(5):486–93.CrossRef
20.
go back to reference Force M, Park G, Chalikonda D, Roth C, Cohen M, Halegoua-DeMarzio D, Hann HW. Alpha-fetoprotein (AFP) and AFP-L3 is most useful in detection of recurrence of Hepatocellular Carcinoma in patients after Tumor ablation and with Low AFP Level. VIRUSES-BASEL 2022, 14(4). Force M, Park G, Chalikonda D, Roth C, Cohen M, Halegoua-DeMarzio D, Hann HW. Alpha-fetoprotein (AFP) and AFP-L3 is most useful in detection of recurrence of Hepatocellular Carcinoma in patients after Tumor ablation and with Low AFP Level. VIRUSES-BASEL 2022, 14(4).
21.
go back to reference Valerievich YA, Rudiansyah M, Chupradit S, Kadhim MM, Turki JA, Abdelbasset WK, Suksatan W, Mireya RPR, Fakri MY, Abdullaev B, et al. Optical-based biosensor for detection of oncomarker CA 125, recent progress and current status. ANAL BIOCHEM. 2022;655:114750.CrossRef Valerievich YA, Rudiansyah M, Chupradit S, Kadhim MM, Turki JA, Abdelbasset WK, Suksatan W, Mireya RPR, Fakri MY, Abdullaev B, et al. Optical-based biosensor for detection of oncomarker CA 125, recent progress and current status. ANAL BIOCHEM. 2022;655:114750.CrossRef
22.
go back to reference Debnath P, Huirem RS, Dutta P, Palchaudhuri S. Epithelial-mesenchymal transition and its transcription factors. BIOSCIENCE REP 2022, 42(1). Debnath P, Huirem RS, Dutta P, Palchaudhuri S. Epithelial-mesenchymal transition and its transcription factors. BIOSCIENCE REP 2022, 42(1).
23.
go back to reference Manfioletti G, Fedele M. Epithelial-mesenchymal transition (EMT) 2021. INT J MOL SCI 2022, 23(10). Manfioletti G, Fedele M. Epithelial-mesenchymal transition (EMT) 2021. INT J MOL SCI 2022, 23(10).
24.
go back to reference Mittal V. Epithelial mesenchymal transition in Tumor Metastasis. ANNU REV PATHOL-MECH. 2018;13:395–412.CrossRef Mittal V. Epithelial mesenchymal transition in Tumor Metastasis. ANNU REV PATHOL-MECH. 2018;13:395–412.CrossRef
25.
go back to reference Li J, Liao Y, Ran Y, Wang G, Wu W, Qiu Y, Liu J, Wen N, Jing T, Wang H, et al. Evaluation of sensitivity and specificity of CanPatrol technology for detection of circulating Tumor cells in patients with non-small cell Lung cancer. BMC PULM MED. 2020;20(1):274.CrossRefPubMedPubMedCentral Li J, Liao Y, Ran Y, Wang G, Wu W, Qiu Y, Liu J, Wen N, Jing T, Wang H, et al. Evaluation of sensitivity and specificity of CanPatrol technology for detection of circulating Tumor cells in patients with non-small cell Lung cancer. BMC PULM MED. 2020;20(1):274.CrossRefPubMedPubMedCentral
26.
go back to reference Qi LN, Xiang BD, Wu FX, Ye JZ, Zhong JH, Wang YY, Chen YY, Chen ZS, Ma L, Chen J, et al. Circulating Tumor cells undergoing EMT provide a Metric for diagnosis and prognosis of patients with Hepatocellular Carcinoma. CANCER RES. 2018;78(16):4731–44.CrossRefPubMed Qi LN, Xiang BD, Wu FX, Ye JZ, Zhong JH, Wang YY, Chen YY, Chen ZS, Ma L, Chen J, et al. Circulating Tumor cells undergoing EMT provide a Metric for diagnosis and prognosis of patients with Hepatocellular Carcinoma. CANCER RES. 2018;78(16):4731–44.CrossRefPubMed
27.
go back to reference Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, et al. Circulating Tumor cells, Disease progression, and survival in metastatic Breast cancer. NEW ENGL J MED. 2004;351(8):781–91.CrossRefPubMed Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, et al. Circulating Tumor cells, Disease progression, and survival in metastatic Breast cancer. NEW ENGL J MED. 2004;351(8):781–91.CrossRefPubMed
28.
go back to reference Bork U, Rahbari NN, Scholch S, Reissfelder C, Kahlert C, Buchler MW, Weitz J, Koch M. Circulating tumour cells and outcome in non-metastatic Colorectal cancer: a prospective study. BRIT J CANCER. 2015;112(8):1306–13.CrossRefPubMedPubMedCentral Bork U, Rahbari NN, Scholch S, Reissfelder C, Kahlert C, Buchler MW, Weitz J, Koch M. Circulating tumour cells and outcome in non-metastatic Colorectal cancer: a prospective study. BRIT J CANCER. 2015;112(8):1306–13.CrossRefPubMedPubMedCentral
29.
go back to reference Chen J, Ye C, Dong J, Cao S, Hu Y, Situ B, Xi X, Qin S, Xu J, Cai Z, et al. Metabolic classification of circulating Tumor cells as a biomarker for Metastasis and prognosis in Breast cancer. J TRANSL MED. 2020;18(1):59.CrossRefPubMedPubMedCentral Chen J, Ye C, Dong J, Cao S, Hu Y, Situ B, Xi X, Qin S, Xu J, Cai Z, et al. Metabolic classification of circulating Tumor cells as a biomarker for Metastasis and prognosis in Breast cancer. J TRANSL MED. 2020;18(1):59.CrossRefPubMedPubMedCentral
30.
go back to reference Markiewicz A, Ksiazkiewicz M, Welnicka-Jaskiewicz M, Seroczynska B, Skokowski J, Szade J, Zaczek AJ. Mesenchymal phenotype of CTC-enriched blood fraction and lymph node Metastasis formation potential. PLoS ONE. 2014;9(4):e93901.CrossRefPubMedPubMedCentral Markiewicz A, Ksiazkiewicz M, Welnicka-Jaskiewicz M, Seroczynska B, Skokowski J, Szade J, Zaczek AJ. Mesenchymal phenotype of CTC-enriched blood fraction and lymph node Metastasis formation potential. PLoS ONE. 2014;9(4):e93901.CrossRefPubMedPubMedCentral
31.
go back to reference Burr R, Gilles C, Thompson EW, Maheswaran S. Epithelial-mesenchymal plasticity in circulating Tumor cells, the precursors of Metastasis. ADV EXP MED BIOL. 2020;1220:11–34.CrossRefPubMed Burr R, Gilles C, Thompson EW, Maheswaran S. Epithelial-mesenchymal plasticity in circulating Tumor cells, the precursors of Metastasis. ADV EXP MED BIOL. 2020;1220:11–34.CrossRefPubMed
32.
go back to reference Jie XX, Zhang XY, Xu CJ. Epithelial-to-mesenchymal transition, circulating Tumor cells and cancer Metastasis: mechanisms and clinical applications. Oncotarget. 2017;8(46):81558–71.CrossRefPubMedPubMedCentral Jie XX, Zhang XY, Xu CJ. Epithelial-to-mesenchymal transition, circulating Tumor cells and cancer Metastasis: mechanisms and clinical applications. Oncotarget. 2017;8(46):81558–71.CrossRefPubMedPubMedCentral
33.
go back to reference Vardas V, Politaki E, Pantazaka E, Georgoulias V, Kallergi G. Epithelial-to-mesenchymal transition of Tumor cells: cancer progression and Metastasis. INT J DEV BIOL. 2022;66(1–2–3):277–83.CrossRefPubMed Vardas V, Politaki E, Pantazaka E, Georgoulias V, Kallergi G. Epithelial-to-mesenchymal transition of Tumor cells: cancer progression and Metastasis. INT J DEV BIOL. 2022;66(1–2–3):277–83.CrossRefPubMed
34.
go back to reference Zhang S, Wu T, Peng X, Liu J, Liu F, Wu S, Liu S, Dong Y, Xie S, Ma S. Mesenchymal phenotype of circulating Tumor cells is associated with distant Metastasis in Breast cancer patients. CANCER MANAG RES. 2017;9:691–700.CrossRefPubMedPubMedCentral Zhang S, Wu T, Peng X, Liu J, Liu F, Wu S, Liu S, Dong Y, Xie S, Ma S. Mesenchymal phenotype of circulating Tumor cells is associated with distant Metastasis in Breast cancer patients. CANCER MANAG RES. 2017;9:691–700.CrossRefPubMedPubMedCentral
Metadata
Title
Significance of circulating tumor cells detection in tumor diagnosis and monitoring
Authors
Yuanrui Liu
Rong Zhao
Zaichun Xie
Zhiyu Pang
Shengjie Chen
Qian Xu
Zhanfeng Zhang
Publication date
01-12-2023
Publisher
BioMed Central
Keyword
Metastasis
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11696-3

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine